Opiant Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
September 06 2017 - 7:00AM
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty
pharmaceutical company developing pharmacological treatments for
addictions, today announced that Roger Crystal, M.D., Chief
Executive Officer, will present at the Rodman & Renshaw 19th
Annual Global Investment Conference in New York on Tuesday,
September 12, 2017 at 8:45 a.m. ET.
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical
company developing pharmacological treatments for addictions. NIDA,
a division of the National Institutes of Health (NIH), describes
these disorders as chronic relapsing brain diseases which burden
society at both the individual and community levels. With its
innovative opioid antagonist nasal delivery technology, Opiant is
positioned to become a leader in these treatment markets. Its first
product, NARCAN® Nasal Spray, is approved for marketing in the U.S.
and Canada by the company’s partner, Adapt Pharma Operations
Limited. For more information please visit: www.opiant.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements relate to future events or our future
financial performance and involve known and unknown risks,
uncertainties and other factors that may cause our or our
industry’s actual results, levels of activity, performance or
achievements to be materially different from any future results,
levels of activity, performance or achievements expressed, implied
or inferred by these forward-looking statements, including those
risks and uncertainties described in our filings with the U.S.
Securities and Exchange Commission, including our most recent
reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.
Therefore, current and prospective security holders are cautioned
that there also can be no assurance that the forward-looking
statements included in this press release will prove to be
accurate. In light of the significant uncertainties inherent in the
forward-looking statements included herein, the inclusion of such
information should not be regarded as a representation or warranty
by Opiant or any other person that the objectives and plans of
Opiant will be achieved in any specified time frame, if at all. In
some cases, you can identify forward-looking statements by
terminology such as “may,” “will,” “should,” “could,” “would,”
“expects,” “plans,” “intends,” “anticipates,” “believes,”
“estimates,” “predicts,” “projects,” “potential,” or “continue” or
the negative of such terms and other comparable terminology. These
statements are only predictions based on our current expectations
and projections about future events. You should not place undue
reliance on these statements. Actual events or results may differ
materially. In evaluating these statements, you should specifically
consider various factors. These and other factors may cause our
actual results to differ materially from any forward-looking
statement. We undertake no obligation to update any of the
forward-looking statements after the date of this press release to
conform those statements to reflect the occurrence of unanticipated
events, except as required by applicable law.
CONTACT INFORMATION:
Corporate Contact:
Investor.relations@opiant.com
Investors:
Sam Martin
Argot Partners
sam@argotpartners.com
212-600-1902
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Apr 2023 to Apr 2024